| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fc6c2e9e63b6561f2f46b1de31f6379 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-422
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 |
| filingDate |
2002-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_648824c55193bfcd24d109af8c592d00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_861d7e060910208c2e53f3d89d4c3917
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3eda3548f2656e9f9ac45f4f454a9ff |
| publicationDate |
2003-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2003004191-A1 |
| titleOfInvention |
Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
| abstract |
Treatment with a cyclooxygenase-2 inhibitor and a leukotriene A 4 hydrolase inhibitor is described as being useful in reducing recipient rejection of transplanted organs and for treatment of autoimmune diseases. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009111794-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8367719-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8344008-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8357684-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009258854-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2336125-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010132599-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8399465-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7939527-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7935725-B2 |
| priorityDate |
1996-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |